ResMed (NYSE:RMD) CEO Michael Farrell Sells 4,991 Shares

12 Mar 2026, 10:04 by Renee Jackson · The Cerbat Gem

ResMed Inc. (NYSE:RMD – Get Free Report) CEO Michael Farrell sold 4,991 shares of the business’s stock in a transaction on Monday, March 9th. The shares were sold at an average price of $251.03, for a total transaction of $1,252,890.73. Following the sale, the chief executive officer owned 466,223 shares of the company’s stock, valued at approximately $117,035,959.69. This represents a 1.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

ResMed Stock Performance

ResMed stock traded down $1.98 during trading on Thursday, reaching $238.17. The company had a trading volume of 54,464 shares, compared to its average volume of 1,074,632. The firm’s 50-day simple moving average is $255.49 and its 200 day simple moving average is $259.12. ResMed Inc. has a 52 week low of $199.92 and a 52 week high of $293.81. The company has a current ratio of 3.06, a quick ratio of 2.32 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $34.70 billion, a price-to-earnings ratio of 23.54, a price-to-earnings-growth ratio of 1.64 and a beta of 0.88.

ResMed (NYSE:RMD – Get Free Report) last released its earnings results on Thursday, January 29th. The medical equipment provider reported $2.81 earnings per share for the quarter, beating analysts’ consensus estimates of $2.68 by $0.13. The company had revenue of $1.42 billion for the quarter, compared to analysts’ expectations of $1.40 billion. ResMed had a net margin of 27.53% and a return on equity of 25.20%. ResMed’s revenue for the quarter was up 11.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.43 EPS. Sell-side analysts forecast that ResMed Inc. will post 9.47 earnings per share for the current fiscal year.

ResMed Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 19th. Shareholders of record on Thursday, February 12th will be paid a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 1.0%. The ex-dividend date is Thursday, February 12th. ResMed’s dividend payout ratio is presently 23.74%.

Analyst Upgrades and Downgrades

RMD has been the topic of several research reports. Royal Bank Of Canada lifted their target price on ResMed from $311.00 to $314.00 and gave the stock an “outperform” rating in a report on Friday, January 30th. Weiss Ratings raised ResMed from a “hold (c+)” rating to a “buy (b-)” rating in a report on Monday, February 9th. UBS Group reiterated a “buy” rating and set a $345.00 target price on shares of ResMed in a research report on Friday, December 12th. Wall Street Zen upgraded shares of ResMed from a “hold” rating to a “buy” rating in a research report on Saturday, February 7th. Finally, Citigroup lifted their price objective on shares of ResMed from $330.00 to $345.00 and gave the stock a “buy” rating in a research note on Monday, February 2nd. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, ResMed presently has a consensus rating of “Moderate Buy” and a consensus price target of $299.27.

Read Our Latest Report on RMD

Institutional Trading of ResMed

A number of large investors have recently modified their holdings of RMD. Jones Financial Companies Lllp grew its position in shares of ResMed by 52.6% in the 1st quarter. Jones Financial Companies Lllp now owns 2,882 shares of the medical equipment provider’s stock worth $645,000 after buying an additional 994 shares during the last quarter. Wedbush Securities Inc. raised its stake in shares of ResMed by 12.0% during the 2nd quarter. Wedbush Securities Inc. now owns 3,658 shares of the medical equipment provider’s stock valued at $944,000 after buying an additional 391 shares during the last quarter. Penserra Capital Management LLC lifted its holdings in shares of ResMed by 6,500.0% in the 2nd quarter. Penserra Capital Management LLC now owns 792 shares of the medical equipment provider’s stock valued at $204,000 after buying an additional 780 shares during the period. Aviva PLC boosted its stake in shares of ResMed by 23.4% in the second quarter. Aviva PLC now owns 89,541 shares of the medical equipment provider’s stock worth $23,102,000 after buying an additional 16,985 shares during the last quarter. Finally, Acadian Asset Management LLC grew its holdings in ResMed by 5,074.8% during the second quarter. Acadian Asset Management LLC now owns 70,791 shares of the medical equipment provider’s stock worth $18,260,000 after acquiring an additional 69,423 shares during the period. Hedge funds and other institutional investors own 54.98% of the company’s stock.

About ResMed

(Get Free Report)

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.